So, let's talk a little bit more about uh T. rexs in response to that question. Is that uh one well identified characteristic of conventional high dose IL2 and even lower doses of IL2 that has been um actually exploited in the setting of bone marrow transplantation. Um, and sometimes in the setting of solid organ transplantation to get or in autoimmunity to get Tregs, is that you see with high dosy too. Uh, increases in T. regs in the circulation. Uh, this has not been apparent with the dosing strategy that they've used with Nembaloin so far, and you measure this primarily. As a phenotypic assay, looking at IO2 receptor alpha high CD4 positive cells in the periphery, and those that when you permobilize them express a transcription factor known as FOB3. Um, an additional suite of studies, uh, that could be done, uh, would be to show that operationally, the ability to suppress a potent immune response mediated by T cells, like an alloye response that you would have to an MHC mismatched organ or bone marrow transplant, is suppressed uh by T cells in the blood of patients. Um, with high dose I too, but not with, uh, following thembale, and I think those studies could be done and, and would provide additional. Uh, information. I also, one of the consequences, uh, interestingly, Of IO2 binding to the high affinity receptor is shedding of the IO2 receptor alpha chain, and one of the suggestions that I've made to the colleagues at Mural is that they measure, even though they're blocking its interaction. With uh cells with their intrinsic IL2 receptor alpha chain, that the cells they're hoping to activate will express once engaging their cogbonate antigen will upregulate IL2 receptor alpha and when they see IL-2, they will shed the L2 receptor alpha chain. And so measuring serum concentrations of IL2 receptor alpha chain, I think would be an additional. Investigative strategy that may pay uh pay for.
Presenter
